Genmab AS (GMAB) — Cash Flow Quality Index
Genmab AS (GMAB) has a Cash Flow Quality Index of 9.72x as of December 2025. Operating cash flow of $300.34 Million exceeds net income of $30.91 Million, indicating high earnings quality where cash backs reported profits. Explore Genmab AS (GMAB) investment intensity to see how much of total assets are deployed in long-term investments.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Genmab AS Cash Flow Quality Index (2013–2025)
Historical Cash Flow Quality Index for Genmab AS across 13 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check GMAB intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Genmab AS (2013–2025)
Year-by-year earnings quality comparison for Genmab AS. For live market cap and the full company financial profile, see market cap of Genmab AS.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 1.23x | $1.19 Billion | $963.76 Million | ▲ +24.3% |
| 2024 | 0.99x | $7.77 Billion | $7.84 Billion | ▼ -24.3% |
| 2023 | 1.31x | $7.38 Billion | $5.64 Billion | ▲ +135.4% |
| 2022 | 0.56x | $3.91 Billion | $7.04 Billion | ▼ -0.6% |
| 2021 | 0.56x | $2.23 Billion | $3.98 Billion | ▼ -58.6% |
| 2020 | 1.35x | $6.43 Billion | $4.76 Billion | ▲ +191.5% |
| 2019 | 0.46x | $1.33 Billion | $2.86 Billion | ▼ -26.3% |
| 2018 | 0.63x | $1.01 Billion | $1.61 Billion | ▼ -57.9% |
| 2017 | 1.49x | $1.59 Billion | $1.06 Billion | ▲ +415.2% |
| 2016 | 0.29x | $327.72 Million | $1.13 Billion | ▼ -29.5% |
| 2015 | 0.41x | $311.45 Million | $757.53 Million | ▼ -7.9% |
| 2014 | 0.45x | $132.67 Million | $297.35 Million | ▲ +137.5% |
| 2013 | -1.19x | $-128.00 Million | $107.64 Million | — |